05 Jun Novo Nordisk and Eli Lillys GLP-1s investment case just became even more compelling As published in FA News on 30 May 2024 By Philip Short Flagship Asset Management fund manager The investment case for Novo Nordisk and Eli Lilly became even more compelling last week after a study found that the fast-selling weight loss GLP-1 drug semaglutide, sold as Ozempic and Wegovy, helps protect the kidney function of overweight or heart disease patients
Injection sites must be shifted each week to avoid skin irritation between the abdomen, upper thigh, or the backs of the upper arms
Factors such as poor lifestyle and diet habits, disruptions in thyroid function, hormonal changes such as menopause and andropause, surgeries, and much more can make meaningful weight loss seem nearly impossible
In this episode, I divide all three drug names into syllables, talk about tocilizumabs suffix, tell you which syllables to emphasize, and share my sources
The higher dose of 0.14 mol/kg had even greater effects, with less than 25% of radioactivity remaining in the stomach after 15 minutes
Each pen or autoinjector should be used by only one person